Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma

International Journal of Gynecological Cancer

Volumn 22, Issue 4, 2012, Pages 617-622

  Vandenput, Ingrid ^a   Vergote, Ignace ^a   Neven, Patrick ^a   Amant, Frédéric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Advanced disease; Endometrial cancer; Paclitaxel carboplatin; Recurrence; Weekly regimen

Indexed keywords

APREPITANT; CARBOPLATIN; CETIRIZINE; DEXAMETHASONE; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; SURVIVAL TIME; TREATMENT RESPONSE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOSARCOMA; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84863688937     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31824a3385     Document Type: Article

References (13)

1. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366:591-605.
2. Hoskins P, Swenerton K, Pike J, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001;19:4048-4053.
3. Sovak M, Dupont J, Hensley M, et al. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer. 2007;17:197-203.
4. Tropé C, Alektiar K, et al. Corpus: epithelial tumors. In: Hoskins W, Perez C, eds. Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:856.
5. Vandenput I, Van Calster B, Capoen A, et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer. 2009;101:244-249.
6. van der Burg ME, van der Gaast A, Vergote I, et al. What is the role of dose-dense therapy? Int J Gynecol Cancer. 2005;15(suppl 3):233-240.
7. Cadron I, Leunen K, Amant F, et al. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. Gynecol Oncol. 2007;106:354-361.
8. Vandenput I, Vergote I, Leunen K, et al. Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. Int J Gynecol Cancer. 2009;19:1147-1151.
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
10. Rowinsky EK, Chaudhry V, Cornblath DR, et al. Neurotoxicity of taxol. J Natl Cancer Inst Monogr. 1993;15:107-115.
11. Secord AA, Havrilesky LJ, Carney ME, et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol. 2007;12:31-36.
12. Tabata T, Tanida K, Umekawa T, et al. Weekly low dose paclitaxel and carboplatin therapy in gynecological cancer patients with venous thrombosis. Anticancer Res. 2008;28:3971-3975.
13. Ito K, Tsubamoto H, Itani Y, et al. A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial). Gynecol Oncol. 2011;120:193-197.